Preveon adefovir dipivoxil nucleotide analog reverse transcriptase inhibitor: Phase II

Results from 29 patients in the first dose cohort in a double-blind placebo-controlled Phase II study in patients infected with hepatitis B virus (HBV) demonstrated that adefovir treatment could reduce levels of HBV to below the limit of detection in the majority of patients.

Using the branched chain DNA assay, treatment with 30 mg adefovir once per day for 12 weeks produced a ?2.44 log drop in HBV DNA compared to a 0.32 log drop with placebo (p<0.001). Using the more sensitive PCR assay, adefovir treatment gave a 4.12 log drop in HBV DNA (p<0.001 versus placebo). ...